Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Diversity and genomic determinants of the microbiomes associated with COVID-19 and non-COVID respiratory diseases

M. Nazmul Hoque a,*, M. Shaminur Rahman b, Rasel Ahmed c, Md. Sabbir Hossain c, Md. Shahidul Islam c, Tofazzal Islam d, M. Anwar Hossain b, e, Amam Zonaed Siddiki f, **

a Department of Gynecology, Obstetrics and Reproductive Health, Bangabandhu Sheikh Mujibur Rahman Agricultural University (BSMRAU), Gazipur 1706, Bangladesh
b Department of Microbiology, University of Dhaka, Dhaka 1000, Bangladesh
c Bangladesh Jute Research Institute, Dhaka 1207, Bangladesh
d Institute of Biotechnology and Genetic Engineering (IBGE), BSMRAU, Gazipur 1706, Bangladesh
e Vice-Chancellor, Jashore University of Science and Technology, Jashore 7408, Bangladesh
f Department of Pathology and Parasitology, Chattogram Veterinary and Animal Sciences University (CVASU), Chattogram 4202, Bangladesh

ARTICLE INFO

Keywords:
COVID-19
SARS-CoV-2
Non-COVID
COPD
URTI
Microbiome
Diversity

ABSTRACT

The novel coronavirus disease 2019 (COVID-19) is a rapidly emerging and highly transmissible disease caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Understanding the microbiomes associated with the upper respiratory tract infection (URTI), chronic obstructive pulmonary disease (COPD) and COVID-19 diseases has clinical interest. We hypothesize that microbiome diversity and composition, and their genomic features are associated with different pathological conditions of these human respiratory tract diseases. To test this hypothesis, we analyzed 21 RNASeq metagenomic data including eleven COVID-19 (BD = 6 and China = 5), six COPD (UK = 6) and four URTI (USA = 4) samples to unravel the microbiome diversity and related genomic metabolic functions. The metagenomic data mapped to 534 bacterial, 60 archaeal and 61 viral genomes with distinct variation in the microbiome composition across the samples (COVID-19 > COPD > URTI). Notably, 94.57%, 80.0% and 24.59% bacterial, archaeal and viral genera shared between the COVID-19 and non-COVID samples, respectively. However, the COVID-19 related samples had sole association with 16 viral genera other than SARS-CoV-2. Strain-level virome profiling revealed 660 and 729 strains in COVID-19 and non-COVID samples, respectively, and of them 34.50% strains shared between the conditions. Functional annotation of the metagenomic data identified the association of several biochemical pathways related to basic metabolism (amino acid and energy), ABC transporters, membrane transport, virulence, disease and defense, regulation of virulence, programmed cell death, and primary immunodeficiency. We also detected 30 functional gene groups/classes associated with resistance to antibiotics and toxic compounds (RATC) in both COVID-19 and non-COVID microbiomes. Furthermore, we detected comparatively higher abundance of cobalt-zinc-cadmium resistance (CZCR) and multidrug resistance to efflux pumps (MREP) genes in COVID-19 metagenome. The profiles of microbiome diversity and associated microbial genomic features found in both COVID-19 and non-COVID (COPD and URTI) samples might be helpful in developing microbiome-based diagnostics and therapeutics for COVID-19 and non-COVID respiratory diseases. However, future studies might be carried out to explore the microbiome dynamics and the cross-talk between host and microbiomes employing larger volume of samples from different ethnic groups and geoclimatic conditions.

1. Introduction

The pneumonia like respiratory illness (COVID-19) caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) was first reported in Wuhan city of China in December, 2019. The disease unprecedentedly spread across 216 countries and/or territories of the globe within months (He et al., 2020; Hoque et al., 2020a; Petersen et al., 2020; Rahman et al., 2020b). The World Health
Organization (WHO) declared the pandemic as a public health emergency of international concern. Metagenomic RNA sequencing of COVID-19 suspected patient’s sample suggested the etiology as a new RNA virus belonging to Coronaviridae and later designated as SARS-CoV-2 (Hoque et al., 2020a; Lam et al., 2020; Rahman et al., 2021). This virus can easily undergo mutation and recombination to adapt diverse environment (Islam et al., 2020), and thus survive by altering (Hoque et al., 2020b) a wide host range causing constant and long-term health threats (Paules et al., 2020). Furthermore, COVID-19 has not only devastated the public health, but also posed an immense impact on human activities at the societal, economical, and geopolitical levels.

The human health services have also been adversely affected by the prevalence, recognition, and management of other non-COVID respiratory diseases including upper respiratory tract infection (URTI), asthma, and chronic obstructive pulmonary disease (COPD) (Stolz et al., 2019; Lippi and Henry, 2020). Although, SARS-CoV-2 affects different people in different ways, most common clinical features include fever, dry cough, tiredness, sore throat, diarrhea, difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement (Hoque et al., 2020b; Islam et al., 2020), many of these symptoms are common in URTI and COPD. The inhaled SARS-CoV-2 virus particle likely binds to epithelial cells in the nasal cavity, starts replicating, migrates down the respiratory tract along the conducting airways, and a more robust innate immune response is triggered (Mason, 2020). Therefore, it can assume that during this propagation, migration and immune response, the microbiomes throughout the respiratory airways could be altered or changed, and some of them can further aggravate the disease process. Recent meta-analysis demonstrated that COPD is the most strongly predictive comorbidity of COVID-19 severity, and is associated with more than five-fold increased risk of COVID-19 infection (Lippi and Henry, 2020). Therefore, patients with a history of non-COVID respiratory diseases such as URTI, asthma and COPD, would be anticipated to have an increased risk of infection (Halpin et al., 2020).

Human health is the outcome of the complex interactions between the inhabiting microbiome and its human host (Kumpitsch et al., 2019). The compositional and functional perturbations of the microbiome can occur at different body sites, and thus, the microbiome dysbiosis can reduce the beneficial and/or commensal bacteria, and favors growth of the opportunistic pathogenic bacteria (Kumpitsch et al., 2019; Hoque et al., 2020b). During COVID-19, and non-COVID respiratory diseases (URTI and COPD), a paradigm shifts in microbiome compositions and their diversity might be observed due to the emergence of particular dominant bacteria in lungs and/or respiratory tract (Hahn et al., 2018; Mathieu et al., 2018; Wypych et al., 2019). The microbial community of the respiratory tract and lung is continually being renewed and replaced, and displays greater variations in both taxonomic composition and diversity (Mathieu et al., 2018; Wypych et al., 2019). Even though bacteria, archaea, viruses, and bacteriophages represent a significant part of the respiratory tract associated microbial communities, to get a deeper understanding of these microbes remains challenging due to the difficulties in their isolation, identification, and characterization. Viruses are essential constituents of microbial communities contributing to their homeostasis and evolution. The viral community in the human gut microbiome is dominated by bacteriophages (Dutilh et al., 2014). Phages can modulate the structure and function of a bacterial community through horizontal gene transfer (HGT), thereby altering the bacterial phenotypes including virulence, antibiotic resistance, and biofilm formation (Huddleston, 2014; Hoque et al., 2019; Zheng et al., 2019). Moreover, phage-induced alterations could pose potential health risks by influencing bacterial pathogenicity and antibiotic resistance (Zheng et al., 2019).

A large body of literature is available on characterization of the clinical features of the COVID-19 patients, the genomic features including structure, composition, evolution, and genome-wide variations in different strains of SARS-CoV-2, and to develop effective vaccine candidates and therapeutics to halt this pandemic disease (Chen et al., 2020; Hoque et al., 2020a; Huang et al., 2020; Rahman et al., 2020a; Rahman et al., 2020b; Rahman et al., 2020c; Rahman et al., 2021). Moreover, several preliminary studies suggested that the composition of a person’s gut microbiome may be predictive of developing severe symptoms of SARS-CoV-2 infections (Chen et al., 2020; He et al., 2020). However, little is known about the potential role of nasopharyngeal and lung microbiomes, and their biological mechanisms for the variable susceptibility to the respiratory diseases. To address the above unresolved question, we investigated the composition, and diversity of microbiomes associated with COVID-19, and non COVID diseases (URTI and COPD). We identified core respiratory microbiota which predicted the proteomic biomarkers of COVID-19 and non-COVID respiratory diseases using high throughput metagenomics sequencing of 21 samples. We conducted further functional metabolic analysis to unravel potential biological mechanisms linking microbiome changes, SARS-CoV-2 genomic diversity, and host disease state. This reports for the first time describe the association of a diverse groups of microbiotas (bacteria, archaea and viruses) and their concomitant genomic features in COVID-19 and non-COVID (URTI and COPD) diseases, and discusses their roles the pathophysiology of these diseases.

2. Methods

2.1. Sample collection and confirmatory diagnosis of COVID-19

The nasopharyngeal specimens were collected from patients (n = 10) presenting with potential COVID-19 infections following the guidance of the Director General of Health Services of Bangladesh. A single dry swab was inserted through one nostril straight back (NOT upwards), along the floor of the nasal passage up to the posterior wall of the nasopharynx, and rubbed against and above the nasal turbinate. The swab was rotated a few times against the nasal wall before removing. A second swab was used to abrade the tonsils and pharynx. The swabs were placed in sample collection vial containing normal saline, and preserved at −20 °C until further use for RNA extraction. The confirmatory diagnosis of SARS-CoV-2 infections were made by RT-qPCR (Peré et al., 2020).

2.2. RNA extraction, metagenomics library preparation and sequencing

We further intended to characterize the microbial community present along with the SARS-CoV-2 virus in the nasopharyngeal specimens of clinical COVID-19 patients through RNASeq metagenomic approach. We extracted total RNA content from five (n = 5) COVID-19 positive patients using TRIzol (Invitrogen) reagent following manufacturer’s protocol. RNA-Seq libraries were prepared from isolated total RNA using TruSeq Stranded Total RNA Library Prep Kit (Illumina) according to the manufacturer’s instructions where first strand cDNA was synthesized using SuperScript II Reverse Transcriptase (Thermo Fisher), and random primers (Visnovska et al., 2019; Zhou et al., 2020). Paired-end (2 x 150 bp reads) sequencing of the RNA library was performed on the Illumina NextSeq 500 platform. RNA extraction, library preparation, and sequencing were carried out at the Basic and Applied Research on Jute Project, Dhaka, Bangladesh.

2.3. Sequence retrieval

In addition to our five COVID-19 RNASeq, we retrieved six (n = 6) Chinese RNASeq data (Accession numbers: SRX770583-1 SRX7705836), four (n = 4) metagenome sequences of human URTI belonged to CDC, USA (Accession numbers: SRR10252885, SRR10252888, SRR10252889 and SRR10252892 under bio-project: PRJNA573045) from the NCBI (National Center for Biotechnology Information) database (https://www.ncbi.nlm.nih.gov/), and six (n = 6) metagenome sequences of human COPD from the European Nucleotide Archive, UK (Accession numbers: ERR2732537, ERR2732541, ERR2732559, ERR2732558, ERR2732551 and ERR2732550 under bio-project:
PRJEB14074). Therefore, the current microbiome study included 21 sequences including 11 COVID-19 (BD = 5, China = 6) and 10 non-COVID (USA = 4, UK = 6) sequences to decipher the microbiome diversity and composition, and metabolic functional potentials associated with COVID-19 (BD and China), and non-COVID respiratory diseases (COPD; UK and URTI; USA).

2.4. Taxonomic mapping, classification, diversity and community analysis

The metagenomic data of the current study were analyzed using the assembly-based hybrid method MG-RAST (release version 4.1) (Glass et al., 2010). The paired-end FASTQ files were concatenated and filtered through BBduk (Stewart et al., 2018) (with options k = 21, mink = 6, ktrim = r, ftrim = 5, qtrim = r, trimq = 20, minlen = 30, overwrite = true) to remove Illumina adapters, known Illumina artifacts, and phiX. Any sequence below these thresholds or reads containing more than one ‘N’ were discarded. In the current study, 46.04 million reads in two metagenomes with an average of 2.19 million reads per sample passed the quality control steps (Supplementary Data 1). The trimmed sequences were uploaded to the MG-RAST server with properly embedded metadata and were subjected to optional quality filtering with dereplication and host DNA removal, and finally screening for taxonomic and functional assignment. Alpha diversity (diversity within samples) was estimated using the observed species, and Shannon diversity indices (Koh, 2018) MG-RAST read assignments and counts. To visualize differences in bacterial diversity, principal coordinate analysis (PCoA) using the NCBI RefSeq database (Kanehisa et al., 2019) and SEED subsystem identification (KEGG) database (Kanehisa et al., 2019), and SEED subsystem identifiers (Glass et al., 2010) on the MG-RAST server using the partially modified set parameters (ε-value cutoff: 1 × 10−30, min. % identity cutoff: 60%, and min. alignment length cutoff: 20).

2.5. Functional profiling of the microbiomes

We performed the taxonomic functional classification through mapping the reads onto the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Kanehisa et al., 2019), and SEED subsystem identifiers (Glass et al., 2010) on the MG-RAST server using the BWA algorithm (Jaillard et al., 2016). Finally, the Pathoscope 2 was used for strain level taxonomic assignment of the viruses (Hong et al., 2014).

2.6. Statistical analysis

The non-parametric test Kruskal-Wallis rank sum test was used to evaluate differences in the relative percent abundance of taxa in COVID-19 and non-COVID (URTI and COPD) sequence data. Comparative taxonomic and functional profiling was performed with the reference prokaryotic metagenomes available in MG-RAST database for statistical analyses. The gene counts were normalized by dividing the number of gene hits to individual taxa/function by total number of gene hits in each metagenome to remove bias due to differences in sequencing efforts. To identify differentially abundant SEED or KEGG functions, and resistance to antibiotics and toxic compounds (RATCs) across the four sampling locations (BD, China, UK and USA), statistical tests were applied with non-parametric test Kruskal-Wallis rank sum test at different KEGG and SEED subsystems levels IBM SPSS (SPSS, Version 23.0, IBM Corp., NY, USA).

3. Results

3.1. Microbiome diversity and composition in COVID-19 and non-COVID samples

The COVID-19 disease significantly affected the diversity (Shannon estimated alpha diversity, \( P = 0.036 \), Kruskal-Wallis test) and composition (Bray-Curtis distance estimated beta diversity, \( P = 0.021 \), Kruskal-Wallis test) of respiratory tract microbiome (Fig. 1). The rarefaction curves showed that sequencing depth was sufficient to capture the entire microbial diversity among the samples of the study (Fig. S1). Both the number of identified microbial taxa and Shannon estimated alpha diversity were significantly higher in COVID-19 samples (BD and China) than the non-COVID (UK and USA) samples (Fig. 1A). The principal coordinate analysis (PCoA) based on Bray-Curtis distances showed distinct separations among the four sampling locations (Bangladesh, China, USA, and UK) (Fig. 1B). Notably, the COVID-19 related samples (BD and China) remained more similar than the URTI and COPD-associated samples from the USA and UK (Fig. 1B). Moreover, the non-COVID respiratory tract disease (URTI and COPD)-associated samples of UK and USA clustered more closely than those of COVID-19 samples (BD and China) indicating that SARS-CoV-2 infections are associated with secondary microbial infections (Fig. 1B).

The composition of COVID-19 (BD and China) and non-COVID respiratory tract disease (URTI; USA and COPD; UK)-related microbiomes at the domain level was dominated by bacteria, with a relative abundance of >99.50, followed by archaea (~0.3%), and viruses (~0.2%) (Data S1). Twenty-eight bacterial phyla were identified in COVID-19 (BD and China), and non-COVID (UK and USA) metagenomes including 28, 10, 28 and 27 phyla in BD, China, UK and USA samples, respectively (Data S1). A total of 534 bacterial genera were detected across the four sample groups including 527, 306, 512 and 443 in BD, China, UK and USA samples, respectively (Data S1). Of the identified bacterial genera shared in both COVID-19 and non-COVID diseases, and only 22 genera had unique association with COVID-19 disease (Fig. 2A, Data S1). In addition to bacteria, 60 archaeal and 61 viral genera were detected, and of them 48, 10, 60 and 31 archaeal genera (Fig. S2B), and 31, 5, 36 and 18 viral genera (Fig. S2C) were identified in BD, China, UK and USA, respectively. Of the detected archaeal genera, 80.0% were found to be shared in both sample groups, and only 20.0% archaeal genera had unique association with non-COVID diseases (Fig. 2B, Data S1). Similarly, 26.23% and 49.18% of the detected viral genera had unique association with COVID-19 and non-COVID diseases, respectively, and 24.59% genera were found to be shared between the conditions (Fig. 2C, Data S1). The strain level profiling of the viral communities revealed 1032 strains including 660 and 729 in the COVID-19 and non-COVID samples, respectively (Fig. 2D, Data S1). Of the identified strains, 303 in COVID-19 and 373 in non-COVID respiratory disease samples, respectively had unique associations, and 34.50% strains were found to be shared between the conditions (Fig. 2D, Data S1).

3.2. Differences in bacteriome composition in COVID-19 and non-COVID samples

The composition of bacterial phyla across the sample groups varied significantly (\( P = 0.037 \), Kruskal-Wallis test). This diversity was represented by the predominant bacterial phyla of Proteobacteria (35.59%), Tenericutes (18.09%), Actinobacteria (17.42%), Cyanobacteria (11.23%), Firmicutes (7.60%), and Bacteroidetes (6.20%) in the COVID-19 metagenome, and Firmicutes (56.47%), Bacteroidetes (14.59%), Actinobacteria (14.12%), and Fusobacteria (2.38%) in non-COVID samples (Fig. 3; Data S1). The rest of the phyla in four in four metagenomes had relatively lower abundances (<1.0%) (Data S1). The composition and relative abundance of the bacteria significantly differed (\( P = 0.029 \), Kruskal-Wallis test) at the genus level between
COVID-19 (BD and China) and non-COVID (UK and URTI) conditions. Remarkably, most of the genera had higher relative abundances in the COVID-19 samples compared to the non-COVID samples (Data S1). Importantly, Staphylococcus (10.39%), Nostoc (6.70%), Ana- baena (4.86%), Mycobacterium (3.02%), Cyanotoce (2.51%), Bradyrhizobium (2.32%), Actinomycites (1.81%), Pseudomonas (1.80%), Propionibacterium (1.56%), Corynebacterium (1.52%), Rhodopseudomonas (1.30%), Nodularia (1.27%), Burkholderia (1.25%), Micrococcus (1.23%), Acinetobacter (1.18%), Methylobacterium (1.15%), Streptomyces (1.14%), Rhodococcus (1.09%), and Rhodobacter (1.00%) were the most abundant archaeal genera detected in both sample groups. Rest of the viral genera detected across the two sample categories, however, their abundances always remained higher in COVID-19 related BD and non-COVID associated UK (COPD) samples (Fig. 6, Data S1). Conversely, Prevotella (18.20%), Streptococcus (17.35%), Veillonella (12.64%), Rothia (9.70%), Actinomyces (7.97%), Neisseria (2.55%), Fusobacterium (2.13%), Lactobacillus (1.97%), Atopobium (1.53%), Megaspheora (1.45%), Porphyromonas (1.41%), Bacteroides (1.34%), Peptostreptococcus (1.28%), Clostridium (1.24%), and Bifidobacterium (1.05%) were the predominantly abundant genera in non-COVID (COPD and URTI) samples of the UK and USA (Fig. 4, Data S1). The rest of the genera detected in both COVID-19 and non-COVID respiratory disease group had less than 1.00% relative abundances (Data S1).

3.3. Differences in archaea and viruses in COVID-19 and non-COVID metagenomes

The archaeal and viral fractions of microbiomes in COVID-19 (BD and China), and non-COVID respiratory disease (COPD; UK and URTI; USA)-metagenomes were concomitantly detected with bacteria. The composition and relative abundance of these two domains varied significantly (P = 0.017, Kruskal-Wallis test) between the COVID-19 and non-COVID samples (Data S1). Among the identified archaeal components of the microbiome, Methanosarcina (19.3%), Methanocaldococcus (17.76%), Thermococcus (10.30%), Methanobacterium (10.28%), Halocella (7.77%), Staphylothermus (6.01%), Natronomonas (5.38%), Ferroglobus (3.52%), Caldairva (3.38%), Halobacterium (2.83%), Natrialba (2.18%), Methanosphaera (2.08%), and Picrophilus (2.02%) were the predominantly abundant genera in COVID-19 samples (Fig. 5, Data S1). Conversely, Methanobrevibacter (10.84%), Methanococcus (10.17%), Methanocorpusculum (6.97%), Pyrococcus (4.76%), Methanospirillum (4.24%), Methanococcoides (3.52%), Methanosaeta (2.55%), Archaeoglobus (2.48%), Methanospirillum (2.40%) and Methanocellus (2.26%) were the most abundant archaeal genera in the non-COVID respiratory disease associated samples (Fig. 5, Data S1). Though the rest of the archaeal genera had lower relative abundances (<2.0%) in both sample categories, however, their abundances always remained higher in COVID-19 related BD and non-COVID associated UK (COPD) samples (Fig. 5, Data S1).

The viral fraction of the microbiome was largely dominated by Betacoronavirus (99.67% of the total abundance) genus in the COVID-19 related samples (BD; 99.55% and China; 99.98%) while the relative abundance of this genus was 39.78% in the non-COVID samples. In addition, Siphovirus (33.17%), Alphapapillomavirus (12.01%), and Myxovirus (7.16%) were the most predominant viral genera in non-COVID samples (Fig. 6, Data S1). Rest of the viral genera detected across the both sample groups had lower relative abundances (<1.0%) (Data S1). The COVID-19 samples from BD and China had sole association of 16 viral genera (other than betacoronavirus), and of them, Tombavirus, Victorivirus, Partitiviruses, Chrysoviruses and Tovivirus were the most abundant genera (Data S2).

Complex microbial communities can harbor multiple strains of the same species which was evident in the present study since the strains of associated viral genera varied significantly (P = 0.033, Kruskal-Wallis test) between the COVID-19 and non-COVID samples. The relative abundances of the identified viral strains also varied between the sample categories since the COVID-19 related samples had the single most predominantly abundant (63.78%) strain of SARS-CoV-2, and remarkably, this strain was not detected in the non-COVID samples. The COVID-related samples of BD and China also possessed Choristoneura fumiferana granulovirus (13.17%), Shamonda orthobunyavirus (3.64%) and Tupaiid betaherpesvirus 1 (1.46%) (Fig. 7A, Data S1). On the other hand, Simbu orthobunyavirus (13.26%), Proteus phage VB.PmIS-Ishahan (11.37%), Mycobacterium phage Enkosi (9.22), BeAn 58058 virus (8.27%), Kaisodi virus (5.00%), Mycobacterium phage Phrxu (3.33%), Beilong virus (2.88%), Mollivirus sibericum (2.77%), Oxbow virus (2.21%) and Micromonas sp. RCC1109 virus MvpV1 (2.1%) were the top abundant viral strains in non-COVID samples of UK and USA (Fig. 7B, Data S1). Phylogenetic analysis revealed that the SARS-CoV-2 strain found in COVID-19 patients showed neighboring relationship to SARS Coronavirus Tor2, Belhai hermit crab virus 4 and Penicillium aurantiogriseum partitivirus 1 (Fig. 7A).

3.4. Differences in metabolic functions in COVID-19 and non-COVID samples

By comparing the number of genes assigned to each KEGG pathway among the groups, we found a series of significant differences (P = 0.006, Kruskal-Wallis test) that lead to the functional divergence in the COVID-19 (BD and China), and non-COVID respiratory disease (COPD; UK and URTI; USA)-associated microbiomes. In the comparative analysis of predicted KEGG orthology (KO), we found that the COVID-19 associated microbiomes harbored relatively higher abundance of genes coding for amino acid metabolism (55.23%; BD = 63.79% and China = 76.67%), energy metabolism (11.01%; BD = 9.81% and China = 12.22%), membrane transport (68.00%; BD = 62.09% and China = 73.90%), ABC transporters (67.89%; BD = 89.91% and China = 65.87%), replication and repair (28.74%; BD = 23.25% and China = 34.23%), flagellar assembly (42.22%; BD = 35.31% and China = 49.13%), and primary immunodeficiency diseases (56.18%; BD = 71.11% and China = 63.24%) compared to the non-COVID related microbiomes of COPD (UK) and URTI (USA)-associated metagenomes (Fig. 8A, Data S2). On the other hand, the non-COVID respiratory disease (COPD and URTI)-associated microbiomes had over expression of genes coding for oxidative phosphorylation (61.30%; UK = 67.22% and USA = 55.38%), signal transduction (50.91%; UK = 46.08% and USA = 75.74%), infectious diseases (59.95%; UK = 67.11% and USA = 52.79%), bacterial chemotaxis (53.79%; UK = 85.00% and USA = 22.58%), and bacterial secretion systems (29.38%; UK = 23.76% and USA = 35.00%) than the COVID-19 related microbiomes (Fig. 8A, Data S2).

The SEED subsystems in the COVID-19 (BD and China) and non-COVID (COPD; UK and URTI; USA)-related microbial communities significantly (P = 0.024, Kruskal-Wallis test) varied. The COVID-19 related microbiomes had relatively higher abundance of genes encoding for pathogenicity islands (21.55%; BD = 18.69% and China = 24.42%), clustering-based subsystems (21.15%; BD = 22.23% and China = 20.07%), regulation of virulence (20.34%; BD = 24.41% and China = 16.28%), biofilm adhesion biosynthesis (18.49%; BD = 11.58% and China = 25.40), adhesion (17.96%; BD = 16.77% and China = 19.13%), programmed cell death (13.53%; BD = 14.85% and China = 12.21%), membrane transport (6.66%; BD = 7.83% and China = 8.50%), gene transfer agent (5.00%; BD = 5.88% and China = 4.12%) and virulence, disease and defense (3.39%; BD = 3.78% and China = 3.00%) (Fig. 8B, Data S2). In contrast, genes coding for oxidative stress (48.75%; UK = 41.89%, USA = 65.60%), periplasmic stress (6.49%; UK = 10.40%, USA = 2.56), cell division (4.65%; UK = 3.29%, USA = 6.01%), invasion and intracellular resistance (2.88%; UK = 1.70%, USA = 4.06%), and phages, prophages and transposable elements (1.26%; UK = 1.40%, USA = 1.11%) were upregulated in the non-COVID related COPD and URTI causing microbiomes (Fig. 8B, Data S2).
The resistome analysis of the COVID-19 (BD and China) and non-COVID (UK and USA)-associated microbiomes, the SEED module of the MG-RAST pipeline provided a comprehensive scenario. Using SEED, 150,146 reads mapped to 30 resistance to antibiotics and toxic compounds (RATC) functional groups across the sample across the four geographic regions, with different relative abundances (Data S2). The RATC genes were classified into two unique groups such as antibiotic resistance ($n = 17$) and toxic metal resistance ($n = 13$) group. Among the RATC functional groups, cobalt-zinc-cadmium resistance (CZCR) had higher relative abundances in COVID-19 microbiomes (23.69%; BD = 25.85%, China = 21.53%) compared to non-COVID (10.34%; UK = 11.75%, USA = 8.92%) microbiomes (Fig. 9; Data S2). Moreover, the RATC functional genes associated with beta lactamase (BLAC) (13.55%; BD = 9.23% and China = 17.87%), copper homeostasis (CH) (11.18%; BD = 12.33% and China = 10.02%), multidrug resistance efflux pumps (MREP) (10.97%; BD = 14.75% and China = 7.19%), multidrug resistance cluster (mdt-ABCD) (5.34%; BD = 4.57% and China = 6.11%), arsenic resistance (AR) (4.76%; BD = 6.27% and China = 3.26%) and multidrug-efflux-pump in Campylobacter jejuni (OneABC) operon (1.86%; BD = 2.74% and China = 0.98%) had higher relative abundances in the COVID-19 associated microbiomes than the non-COVID respiratory disease (COPD and URTI) causing microbiomes (Fig. 9; Data S2). Conversely, genes coding for resistance to fluoroquinolones (RFL) (22.31%; UK = 26.16%, USA = 18.46%), BlaR1-Family-Regulatory-Sensor-Transducer-Disambiguation (BlaR1) family (15.47%; UK = 9.71% and USA = 21.23%), methicillin resistance in Staphylococcus (MRS) (8.20%; UK = 10.55% and USA = 5.85%), resistance to chromium compounds (RCHC) (5.11%; UK = 1.05%, USA = 9.23%), Streptococcus pneumonia-vancomycin-tolerance-locus (SPVANT) (3.39%; UK = 3.71%, USA = 3.07%), mercury resistance to operon (MRO) (2.34%; UK = 2.53% and USA = 2.15%) and copper homeostasis: copper tolerance (CHCT) (2.07%; UK = 2.91%, USA = 1.23%) were found to be over expressed in the COPD and URTI-associated non-COVID microbiomes (Fig. 9, Data S2). Rest of the RATC genes detected in both metagenomes also varied in their relative abundances.

4. Discussion

The present study represents a proof-of-concept to decipher changes in microbiome compositions and diversity in COVID-19 (BD and China), and non-COVID related chronic obstructive pulmonary disease; COPD (UK), and upper respiratory tract infection; URTI (USA). Several recent studies showed that COVID-19 is associated with dysbiosis of the gut microbiomes (Dhar and Mohanty, 2020; Zuo et al., 2020). Respiratory tract especially lung microbiome is more dynamic and transient than that of the gastrointestinal tract because of bidirectional movement of air and mucus (Huffnagle et al., 2017). This makes it plausible that SARS-CoV-2 infections could lead to abnormal inflammatory reactions to worsen the symptoms of COVID-19. The microbiome diversity (alpha and beta diversity) measures revealed higher microbial diversity in COVID-19 samples which remained more similar than the URTI and COPD-associated samples from the USA and UK. Regardless of higher taxonomic abundances, the COVID-19-associated microbiomes remained inconsistent and fluctuate more within BD and China metagenomes than those of UK and USA samples. In a recent study, Zuo et al. (2020) reported that loss of salutary species in COVID-19 persisted in most patients despite clearance of SARS-CoV-2 virus, and is associated with a more long-lasting detrimental effect to the gut microbiome.

In this study, the dominant microbial phyla showed no significant difference between two groups, however, COVID-19 still affected the prevalence of some microbes belonged to Proteobacteria and Cyanobacteria corroborating the recent findings of Khatiwada and Subedi (2020).

To be specifically, in COVID-19 samples of BD and China, the abundance of Proteobacteria, Tenericutes, and Cyanobacteria were significantly higher. Conversely, Firmicutes, Actinobacteria, Bacteroidetes, and Fusobacteria were the predominant phyla in COPD and URTI samples of UK and USA, respectively. These findings are accorded with previous studies of respiratory tract disease associated microbiome dysbiosis (Singh et al., 2017; Hahn et al., 2018; Li et al., 2019). The healthy respiratory tract and lungs microbiomes are mostly represented by Firmicutes, Bacteroidetes and Proteobacteria phyla (Khatiwada and Subedi, 2020) suggesting inclusion of other predominant opportunistic phyla such as Tenericutes, Cyanobacteria, Actinobacteria, and Fusobacteria in the COVID-19 samples of BD and China. The COVID-19 and non-COVID (COPD and URTI)-patients had an enrichment of pathogenic and commensal bacteria, indicating a degree of microbial changes in diseased states. We demonstrated that in the SARS-CoV-2 infected patients, some genera including Staphylococcus, Nostoc, Anabaena, Mycobacterium, Cyanothecae, Bradyrhizobium, Actinomyces, Pseudomonas, Propionibacterium, Corynebacterium, Rhodopseudomonas, Nodularia, Burkholderia, Micrococcus, Acinetobacter, Methylobacterium, Streptomyces, Rhodococcus, and Rhodobacter had higher relative abundances compared to the non-COVID samples. The changes in the composition and relative abundances of the microbiomes in the respiratory tract is associated with many vital body functions such as immune regulation and pathogenesis (Kampitche et al., 2019), and might be associated with the COVID-19 exacerbations.

The pathophysiology of an inflammation plays an important role in...
Fig. 2. Taxonomic composition of COVID-19 (BD and China) and non-COVID (URTI; USA and COPD; UK) disease metagenomes. Venn diagrams representing the core unique and shared microbiomes in COVID-19 and non-COVID diseases. (A) Venn diagram showing unique and shared bacterial genera. Out of 534 detected bacterial genera, only 13 genera had unique association with COVID-19 while rest of the 521 genera (highlighted in yellow) shared between the condition. (B) Venn diagram comparison of unique and shared archaeal genera where 48 (highlighted in yellow) genera shared between the condition, and 12 genera had unique association with non-COVID URTI (URTI and COPD) diseases. (C) Venn diagrams representing unique and shared viral genera identified in both metagenomes. Of the detected viral genera \( n = 61 \), 16 and 30 genera had unique association with COVID-19 and non-COVID diseases, respectively, and 15 genera (highlighted in yellow) were found to be shared between the study metagenomes. (D) Venn diagrams showing the unique and shared viral strains in COVID-19 and Non-COVID diseases. Out of viral strains detected, 356 strains (highlighted in yellow) shared between the condition while 303 and 373 strains had unique associations with COVID-19 and Non-COVID metagenomes, respectively. More information on the taxonomic results are available in Data S1. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Fig. 3. The phylum level taxonomic profile bacteria in COVID-19 (BD and China), and respiratory tract (UK and USA) disease metagenomes. Stacked bar plots showing the relative abundance and distribution of the 15 top abundant phyla, with ranks ordered from bottom to top by their increasing proportion. The first four bar plots represent the abundance of bacterial phyla in the corresponding category of COVID-19 (BD and China) and non-COVID (URTI; USA and COPD; UK) disease, and the last two bar plots depict overall relative abundance of phyla in COVID-19 and non-COVID metagenomes, respectively. The distribution and relative abundance of the bacterial phyla in the study metagenomes are also available in Data S1.
destroying the invading microbes, and thereby protecting the commensal organisms (Hoque et al., 2020b; Hoque et al., 2020c), but unregulated inflammation is an underlying cause of many chronic diseases like COPD. Our findings demonstrated that the non-COVID-related COPD and URTI patients had the higher relative abundance of certain dominant bacterial genera including Prevotella, Streptococcus, Veillonella, Rothia, Actinomyces, Neisseria, Fusobacterium, Lactobacillus, Atopobium, Megasphaera, Porphyromonas, Bacteroides, Peptostreptococcus, Clostridium, and Bifidobacterium. The inflammatory mediators are associated with parts of dominant microbiome in the lungs, which suggesting that inflammation might impair the structure of growth environment of microbiome and the microbiome changes might in turn promoted the COPD (Ditz et al., 2020) and URTI (Man et al., 2017) inflammations. The upper respiratory tract is generally considered to be a major reservoir for

Fig. 4. The genus level taxonomic profile bacteria in COVID-19 (BD and China) and non-COVID (URTI; USA and COPD; UK) disease metagenomes. Stacked bar plots showing the relative abundance and distribution of the 34 most top abundant bacterial genera, with ranks ordered from bottom to top by their increasing proportion. The first four bar plots represent the abundance of bacteria in the corresponding category of COVID-19 (BD and China) and non-COVID (URTI; USA and COPD; UK) disease, and the last two bar plots depict overall relative abundance of bacterial genera in COVID-19 and non-COVID metagenomes, respectively. Only the 33 most abundant genera are shown in the legend, with the remaining genera grouped as ‘Other genera’. The distribution and relative abundance of the bacterial genera in the study metagenomes are also available in Data S1.

Fig. 5. The genus level taxonomic profile archaea in COVID-19 (BD and China) and respiratory tract disease (UK and USA) metagenomes. Stacked bar plots showing the relative abundance and distribution of the 30 most abundant genera, with ranks ordered from bottom to top by their increasing proportion. The first four bar plots represent the abundance of archaea in the corresponding category of COVID-19 (BD and China) and non-COVID (URTI; USA and COPD; UK) disease, and the last two bar plots depict overall relative abundance of archaeal genera in COVID-19 and non-COVID metagenomes, respectively. Only the 29 most abundant genera are shown in the legend, with the remaining genera grouped as ‘Other genera’. The distribution and relative abundance of the archaeal genera in the study metagenomes are also available in Data S1.
potential pathogens, including *Streptococcus*, *Veillonella*, *Pseudomonas*, *Clostridium*, *Rothia*, and *Neisseria*, to expand and subsequently spread towards the lungs, which could potentially lead to a chronic infection like COPD (Man et al., 2017; Ditz et al., 2020). The findings of the present study suggested that bacteriome composition in COVID-19 and non-COVID associated COPD and URTI might be similar at phylum level, however, could vary significantly at genus and strain levels which might be related to the age, gender, weight, food habit, and different living environment (Wang et al., 2018). Thus, establishing and maintaining a balanced microbiota in the COVID-19 and non-COVID respiratory disease (URTI and COPD) samples that is resilient to pathogenic expansion and invasion could prove vital for respiratory health. Moreover, 94.57% bacterial genera including *Staphylococcus*, *Mycobacterium*, *Burkholderia*, *Prevotella*, *Streptomyces*, *Neisseria*, *Acidovorax*, *Fusobacterium*, *Streptococcus*, *Erythrobacter*, and *Bacteroides* shared between COVID-19 and non-COVID (COPD and URTI) metagenomes suggesting their diverse role in the pathophysiology of human diseases (Man et al., 2017; Ditz et al., 2020; Khatiwada and Subedi, 2020). However, the mechanisms for the pathophysiology of COVID-19 and other respiratory tract diseases (non-COVID) as well as specific host-microbiome interactions supporting the changes in microbiome compositions, are considered below and not well-established.

Viral infections predispose patients to secondary bacterial and archaeal infections, which often have a more severe clinical course (Brundage, 2006; Yildiz et al., 2018; Shen et al., 2020; Zuo et al., 2020). Until now, most of the respiratory tract disease associated microorganisms reported so far are limited to bacteriome composition (Man et al., 2017; Singh et al., 2017; Li et al., 2019; Ditz et al., 2020; Shen et al., 2020) while a plethora of other concomitant microbial components including archaea and viruses could also be detected (Koskinen et al., 2017; Hoque et al., 2019; Hoque et al., 2020b). Unlike bacteria, the diversity and composition of archaea and viruses always remained much lower in COVID-19 and non-COVID (URTI and COPD) samples. The COVID-19 and non-COVID related COPD samples had higher number of archaeal and viral genera with significantly varied relative abundances. Among the identified archaeal components of the microbiomes, the methanogenic archaea *Methanosarcina* was the most abundant genus in both sample groups. Most methanogenic archaea coexist and interact closely with anaerobic bacteria (Hoque et al., 2020b; Hoque et al., 2020c).

Methanogenic archaea utilize low molecular weight compounds, such as H2 + CO2, formic acid, or acetate, and therefore have symbiotic relationships with the producers of these substrates. Therefore, it is reasonable to hypothesize that the presence or increase in level of methanogenic archaea alters the composition of the polymicrobial community thus resulting in changes in virulence of the flora (Maeda et al., 2013; Hoque et al., 2020b; Hoque et al., 2020c). The viral fraction of the microbiome was largely dominated by *Betacoronavirus* genus in the COVID-19 related samples of BD and China. Conversely, the virome fraction of the non-COVID (URTI and COPD) samples were mostly represented by the genera belonged to the order *Caudovirales* which consists of the three families of tailed bacterial viruses (bacteriophages) infecting bacteria and archaea (Hoque et al., 2019; Hoque et al., 2020b). The host range of *Caudovirales* is very broad and includes all major bacterial phyla found in our samples: *Firmicutes*, *Bacteroidetes*, *Proteobacteria* and *Actinobacteria*. This corresponded with an increased relative abundance of these bacterial taxa in COPD and URTI metagenomes. Moreover, the presence of few predominating viral genus both in COVID-19 and non-COVID samples suggests that the crucial differences might be occurring at the strain level, and most of the genus identified in each sample were represented by a single strain. The COVID-19 related samples were dominated by only SARS-CoV-2 strain which was not detected in non-COVID samples. Notably, the other predominant viral species/strains in COVID-19 and non-COVID samples were mostly represented by bacteriophages including *Proteus* phage VB.RpMIS-Isfahani, *Mycobacterium* phage Enkosi, *Mycobacterium* phage Phrux. Bacteriophages are naturally occurring viruses that use bacteria as hosts, and play an extremely important part in allowing relatively harmless bacteria to become pathogens (Huddleston, 2014; Hoque et al., 2019; Zheng et al., 2019). Recent scientific researches provide evidence that bacteriophages are overlooked human pathogens, implied in the triggering, and worsening of a number of human diseases (Zheng et al., 2019). The COVID-19 causing SARS-CoV-2 strain showed neighboring relationship to human classic coronavirus, the *SARS Coronavirus* isolate Tor2 (SARS-CoV Tor2) corroborating with several recent studies (Hou, 2020; Konno et al., 2020). However, our current findings demonstrated that archaea and viruses (other than SARS-CoV-2) neither cause COPD and URTI directly nor play a role in the initiation of the disease process, but later, when bacterial infection of the respiratory tract occurs, they replicate in the...
immune and epithelial cells, and may act as a predisposing factor as well as a primary etiological agent for more severe URTI, and prolonged disease like COPD.

The functional metagenomics analyses provided a promising opportunity for studying microbial-host interactions, and has uncovered significant differences in microbial metabolic functions in COVID-19 and non-COVID metagenomes. In this study, the COVID-19 associated microbiomes harbored relatively higher abundance of genes coding for metabolism (especially for amino acid and energy), ABC transporters, membrane transport, virulence, disease and defense, regulation of virulence, programmed cell death, and primary immunodeficiency diseases compared to non-COVID microbiomes. However, the specific role these altered metabolic pathways in the pathophysiology of the COVID-19 disease is not clearly explored still now. The metabolic activities related to virulence and immunosuppression have profound impact on SARS-CoV-2 infections as evidenced earlier from the SARS and MERS outbreaks (Thng et al., 2021). Most recently, several researchers comprehensively queried the impact of the microbiome on the
metabolome throughout the body, and found that microbiota affected the metabolomics of every organ (Hoque et al., 2020b; Lee-Sarwar et al., 2020; Quinn et al., 2020). The observed increased abundance of genes for primary immune diseases (e.g., adenosine deaminase) in COVID-19 and non-COVID-COPD pathogens is responsible for inhibition of T cell maturation and lymphocytic proliferation, very low CD4 count, cell-to-cell communication and therefore could be used as a selective marker for COVID-19 and COPD diagnosis. We identified several genes as being differentially expressed in COVID-19 microbiomes that were involved in bacterial physiology, such as the bacterial secretion system by which pathogenic bacteria to secrete virulence factors for host invasion (Depluverez et al., 2016). ABC transporters, which contribute to substrate transport across the bacterial membrane and are related to antibiotic resistance (Wilson, 2016; Zhang et al., 2020; Hoque et al., 2020c), were also enriched with differentially expressed genes in the in COVID-19 microbiomes.

The relative abundance and diversity of the genes coding for resistance to antibiotics and toxic compounds (RATC) in the human respiratory microbiome remain poorly characterized. The microbiomes (especially bacterial community) within this potential reservoir are becoming more resistant. In the context of SARS-CoV-2 virus infection, interactions between the virus, the host, and resident bacteria with pathogenic potential are known to complicate and worsen disease, disease associated microbiomes could have a profound impact on the outcome of COVID-19. The correlations of the microbiome composition and diversity in COVID-19 and non-COVID respiratory tract disease (COPD and URTI) related microbial communities. The identifiable changes in the microbiome diversity, composition and associated genomic features demonstrated in this study might be associated with the development, treatment, and resolution of COVID-19. The shared bacterial, archaeal and viral genera detected in this study suggest that respiratory tract disease associated microbiomes could have a profound impact on the pathogenesis of SARS-CoV-2 infection and severity of the disease. Moreover, the predominantly abundant bacterial pathogens along with the archaea and bacterial viruses (phages) could have important contribution for the generation of immune responses against viral attack, and this secondary microbial community might affect the outcome of COVID-19. The correlations of the microbiome composition and diversity in COVID-19 and non-COVID respiratory tract disease (COPD and URTI) determined in this study are also evidenced by the differences in the relative abundances of the genes associated with their concurrent resistomes (RATC) composition and several metabolic functional potentials. However, future studies should be directed to investigate the cross-talks between host and respiratory tract.

Fig. 8. Functional annotation of the COVID-19 (BD and China) and respiratory tract disease (UK and USA) metagenomes. (A) Heatmap representing the average relative abundance hierarchical clustering of the predicted KEGG Orthologs (KOs) functional pathways of the microbiome across four metagenome groups. (B) Heatmap showing the average relative abundance hierarchical clustering of the predicted SEED functions in different levels among the microbiomes of four metagenomes. The color bars (column Z score) at the top represent the relative abundance of putative genes. The color codes indicate the presence and completeness of each KEGG and SEED module, expressed as a value between −2 (lowest abundance) and 2 (highest abundance). The red color indicates the more abundant patterns, while green cells account for less abundant putative genes in that particular metagenome. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

5. Conclusions

The COVID-19 had significant effect on the diversity and composi
tion of respiratory tract microbiomes of human. The COVID-19 associ
ated microbiomes are rich in diversity, composition and functional capacity compared to the non-COVID respiratory disease (COPD and URTI)-related microbial communities. The identifiable changes in the microbiome diversity, composition and associated genomic features demonstrated in this study might be associated with the development, treatment, and resolution of COVID-19. The shared bacterial, archaeal and viral genera detected in this study suggest that respiratory tract disease associated microbiomes could have a profound impact on the pathogenesis of SARS-CoV-2 infection and severity of the disease. Moreover, the predominantly abundant bacterial pathogens along with the archaea and bacterial viruses (phages) could have important contribution for the generation of immune responses against viral attack, and this secondary microbial community might affect the outcome of COVID-19. The correlations of the microbiome composition and diversity in COVID-19 and non-COVID respiratory tract disease (COPD and URTI) determined in this study are also evidenced by the differences in the relative abundances of the genes associated with their concurrent resistomes (RATC) composition and several metabolic functional potentials. However, future studies should be directed to investigate the cross-talks between host and respiratory tract.
microbiomes in a large cohort of COVID-19 patients, and correlate with the severity of the disease. Furthermore, such studies would also be enhanced by the inclusion of gut microbiomes sampling in addition to the COVID-19 sampling for direct testing of microbial transfer across the gut-lung axis.

Supplementary information supporting the findings of the study are available in this article as Data S1 and S2, and Fig. S1. Supplementary data to this article can be found online at https://doi.org/10.1016/j.genrep.2021.101200.

Abbreviations

COVID-19 Coronavirus disease 2019
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus-2
URTI Upper respiratory tract infection (URTI)
COPD Chronic obstructive pulmonary disease (COPD)
RATC Resistance to antibiotics and toxic compounds
CZCR Cobalt-zinc-cadmium resistance
MREP Multidrug resistance to efflux pumps
RNASeqS RNA sequencing
NCBI National center for biotechnology information

Fig. 9. Distribution of the resistance to antibiotic and toxic compounds (RATC) genes in COVID-19 (BD and China) and respiratory tract disease (UK and USA) metagenomes. The circular plot illustrates the diversity and relative abundance of the RATC genes detected among the microbiomes of the four metagenomes through SEED subsystems analysis. The association of the RATC genes according to metagenome is shown by different colored ribbons and the relative abundances these genes are represented by inner blue colored bars. Part of the RATC functional groups are shared among microbes of the four metagenomes (BD, China, UK and USA), and some are effectively undetected in the microbiomes of the other metagenomes. Abbreviations- CZCR: cobalt-zinc-cadmium resistance, MREP: multidrug resistance to efflux pumps, CH: copper homeostasis; BlaR1 Family: BlaR1 family regulatory sensor-transducer disambiguation, RFL: resistance to fluoroquinolones, AR: arsenic resistance, mdtABCD: the mdtABCD multidrug resistance cluster, BLAC: beta-lactamase resistance, OprN: mexe-mexf-oprn multidrug efflux system, CmeABC operon: multidrug efflux pump in Campylobacter jejuni, MRS: methicillin resistance in Staphylococci, MRO: mercury resistance to operon, CHCT: copper homeostasis: copper tolerance, CDR: cadmium resistance, RCHC: resistance to chromium compounds, ZR: zinc resistance, ER: erythromycin resistance, MRD: mercuric reductase, RVAN: resistance to vancomycin, SPIVANT: Streptococcus pneumoniae vancomycin tolerance locus, TRS: teicoplanin-resistance in Staphylococcus, ADCYS: adaptation to d-cysteine, BH: bile hydrolysis, Li: lysozyme inhibitors, PSGCB: polymyxin synthetase gene cluster in Bacillus, oprM: mexA-mexB-oprn multidrug efflux system, AAdNyl: aminoglycoside adenyltransferases, FR: fosfomycin resistance, MAR Locus: multiple antibiotic resistance to locus, OprJ: mexC-mexD-OprJ-multidrug-efflux-system. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Author contributions

MNH conceived and designed the study, performed bioinformatics analysis, visualized figures, interpreted results and drafted the original manuscript. MSR the retrieved sequences, curated the data and performed bioinformatics analysis. RA, MSH and MSI performed sequencing and reviewed the drafted manuscript. TI, MAH and AMAMZS conceived and guided the study, and critically reviewed the drafted manuscript.

Data availability

The sequence data reported in this paper are available in the GISAID (a global science initiative and primary source for genomic data of influenza viruses and the novel coronavirus responsible for COVID-19) database (https://www.gisaid.org) (Accession numbers: SRX7705831-5836, SRX7705834-37). NCBI (National Center for Biotechnology Information) database (Accession number: PRJNA573045), and the ENA (European Nucleotide Archive) (Accession number: PRJEB14074).

Ethics statement

The protocol for sample collection from COVID-19 patients, sample processing, transport, and RNA extraction was approved by the Director General of Health Services of Bangladesh.

Declaration of competing interest

The authors declared no conflict of interest.

Acknowledgements

We are thankful to the COVID-19 patients who provided us with their nasopharyngeal swab samples on request, and those who deposited and shed their sequences to the GISAID, NCBI, and ENA, and make open for the global research community. We are also thankful to Bangladesh Jute Research Institute for to help us in RNA sequencing.

References

Alvarez-Ortega, C., Olives, J., Martinez, J.L., 2013. RND multidrug efflux pumps: what are they good for? Front. Microbiol. 4, 7. https://doi.org/10.3389/fmicb.2013.00007.

Beck, J., Holloway, J.D., Schwanghart, W., 2013. Undersampling and the measurement of beta diversity. Methods Ecol. Evol. 4, 370–382. https://doi.org/10.1111/2041-210X.12023.

Bengtsson-Palme, J., Kristiansson, E. and Larsson, D.J., 2018. Environmental factors influencing the development and spread of antibiotic resistance. FEMS microbiology reviews 42, fau053. doi: 10.1093/femsre/fau053. PMID: 29069382; PMCID: PMC5812547.

Brundage, J.F., 2006. Interactions between influenza and bacterial respiratory disease, particularly, in asthma. Front. Physiol. 9, 1168.

Chang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.

Huddleston, J.R., 2014. Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes. In: Infection and Drug Resistance, 7, p. 167.

Huffnagle, G., Dickson, R., Lakas, N., 2017. The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol. 10, 299–306.

Islam, M.N., Hoque, M.N., Rahman, M.S., Alam, A.R.U., Akhter, M., Papu, A.J., Akter, S., Sultana, M., Crandall, K.A., Hossain, M.A., 2020. Genome-wide analysis of SARS-CoV-2 virus strains circulating worldwide implicates heterogeneity. Sci. Rep. 10, 19805.

Jaillard, M., Tournoud, M., Meynier, F., Veyrieras, J.-B., 2016. Optimization of metagenomics RAST server (MG-RAST) for analyzing shotgun metagenomes. Cold Spring Harb. Protocols 2016, pdb. prot5368; DOI: 10.1101/pdb.prot5368.

Speth, D.R., Seguritan, V., Aziz, R.K., 2014. A highly abundant bacteriophage antagonist whose activity is increased by a naturally occurring elongation variant. J. Bacteriol. 196, 675–679. https://doi.org/10.1128/JB.00870-14.

Tan, X., 2020. Temporal dynamics in viral shedding and transmissibility of COVID-19. Med. J. Aust. 212, 105941.

Wang, H., 2020. Characterization of codon usage pattern in SARS-CoV-2. Virol. J. 17, 100073. https://doi.org/10.1186/s41598-020-00237-0.

He, X., Lau, E.H., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y.C., Wong, J.Y., Guan, Y., Tan, X., 2020. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 26, 672–675. https://doi.org/10.1038/s41591-020-0869-5.

Hou, W., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.

Hou, W., 2020. Characterization of codon usage pattern in SARS-CoV-2. Virol. J. 17, 1–10.

He, X., Lau, E.H., Wu, P., Deng, X., Wang, J., Hao, X., Lau, Y.C., Wong, J.Y., Guan, Y., Tan, X., 2020. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat. Med. 26, 672–675. https://doi.org/10.1038/s41591-020-0869-5.

Hou, W., 2020. Characterization of codon usage pattern in SARS-CoV-2. Virol. J. 17, 1–10.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506.

Koh, H., 2018. An adaptive microbiome α-diversity-based association analysis method. Sci. Rep. 8, 1–12.

Konno, Y., Kimura, I., Uriu, K., Fukushima, M., Irie, T., Koyanagi, Y., Sauter, D., Gifford, R., Nakagawa, J., Sato, K., 2020. SARS-CoV-2 ORF1b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant. Cell Rep. 32, 108185.

Koskinen, K., Pausan, M.R., Perras, A.K., Beck, M., Bang, C., Mora, M., Schibab, A., Schmitz, R., Moisil-Eichinger, C., 2017. First insights into the diverse human archaeosome: specific detection of archaea in the gastrointestinal tract, lung, and nose on and skin. MBio 8.

Kumpitsch, C., Koskinen, K., Schopf, V., Moisil-Eichinger, C. 2019. The microbiome of the upper respiratory tract in health and disease. BMC Biol. 17, 87.

Lam, J., Li, J., Sun, X., Zhan, Y., Li, J., Tang, Y.-G., Shi, Y.-X., Ni, X.-B., Liao, Y.-S., 2020. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 1–4.

Lee-Sarwar, K.A., Lasky-Su, J., Kelley, R.S., Litonjua, A.A., Weiss, S.T., 2020. Metabolome-microbiome crosstalk and human disease. Metabolites 10, 181.

Li, K.-J., Chen, Z.-L., Huang, Y., Zhang, R., Luan, X.-Q., Lei, T.-T., Chen, L., 2019. Dysbiosis of lower respiratory tract microbiome are associated with inflammation and microbiotal function variation. Respir. Res. 20, 1–16.

Lippi, G., Henry, B.M., 2020. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir. Med. 167, 105941.

Maeda, H., Hirai, K., Mineshira, J., Yamamoto, T., Koeck, C., Takanashi, S., 2013. Medical microbiological approach to Archaea in oral infectious diseases. Jpn. Dent. Sci. Res. 49, 72–78.

Man, W.H., de Steenhuijzen Pifers, W.A., Bogaert, D., 2017. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat. Rev. Microbiol. 15, 259–270.

Mason, R.J., 2020. Pathogenesis of COVID-19 from a Cell Biology Perspective (Eur Biopharma Soc).

Mathieu, E., Escobaro-Vazquez, U., Descamps, D., Cherbuy, C., Langella, P., Riffault, S., Remot, A., Thomas, M., 2018. Paradigms of lung microbiota functions in health and disease, particularly, in asthma. Front. Physiol. 9, 1168.

Paules, C.R., Marston, R.D., Pfeffer, S., 2020. Coronavirus infections—more than just the common cold. Jama 323, 707–708.

Pere, H., Podljažen, I., Wack, M., Flamarion, E., Mirault, T., Goudot, G., Hauw-Berlé, C., le, L., Cauadon, E., Carrabin, S., 2020. Nasal swab sampling for SARS-CoV-2: a convenient alternative in times of nasopharyngeal swab shortage. J. Clin. Microbiol. 58.

Peter, S., Koopmans, M., Go, U., Hamer, D.H., Petrosillo, N., Castelli, F., Stegengaard, M., Al Khalili, S., Simonetti, L., 2020. Comparing SARS-CoV with SARS-CoV-2 and influenza pandemics. Lancet Infect. Dis. 20 (9), e238–e244. https://doi.org/10.1016/S1473-3099(20)30484-9.

Gene Reports 23 (2021) 101200 12

Halpin, D.M., Faner, R., Sibila, O., Badia, J.R., Agusti, A., 2020. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir. Med. 8, 436–438.

`
Quinn, R.A., Melnik, A.V., Vrbanac, A., Fu, T., Patras, K.A., Christy, M.P., Bodai, Z., Belda-Ferre, P., Tripathi, A., Chung, L.K., 2020. Global chemical effects of the microbiome include new bile-acid conjugations. Nature 579, 123–129.

Rahman, M., Nazmul Hoque, M., Rubayet Ull Alam, A., Akther, M., Akther Purposo, J., Akther, S., Anwar, A., Sultana, M., Anwar Hossain, M., 2020a. Comprehensive Annotations of the Mutational Spectra of SARS-CoV-2 Spike Protein: A Fast and Accurate Pipeline (Transboundary and Emerging Diseases).

Rahman, M.S., Hoque, M.N., Islam, M.R., Akter, S., Rubayet-Ul-Alam, A., Siddique, M.A., Saha, O., Rahman, M.M., Sultana, M., Crandall, K.A., 2020b. Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2 etiologic agent of global pandemic COVID-19: an in silico approach. PeerJ 8, e9572.

Rahman, M.S, Islam, M.R., Alam, A.R.U., Islam, I., Hoque, M.N., et al., 2021. Evolutionary dynamics of SARS-CoV-2 nucleocapsid protein and its consequences 93 (4), 2177–2195. https://doi.org/10.1002/tdm_license_1.1.

Rahman, M.S., Islam, M.R., Alam, A.R.U., Islam, I., Hoque, M.N., Akter, S., Rahaman, M. M., Sultana, M., Hossain, M.A., 2020c. Evolutionary Dynamics of SARS-CoV-2 Nucleocapsid Protein (N Protein) and its Consequences (BioRxiv).

Shen, Z., Xiao, Y., Kang, L., Ma, W., Shi, L., Zhang, L., Zhou, Z., Yang, J., Zhong, J., Yang, D., 2020. Genomic diversity of SARS-CoV-2 in coronavirus disease 2019 patients. Clin. Infect. Dis. 71 (15), 713–720. https://doi.org/10.1093/cid/ciaa203.

Singh, N., Vats, A., Sharma, A., Arora, A., Kumar, A., 2017. The development of lower respiratory tract microbiome in mice. Microbiome 5, 1–16.

Stewart, R.D., Auffret, M.D., Warr, A., Wiser, A.H., Press, M.O., Langford, K.W., Liachko, I., Snelling, T.J., Dewhurst, R.J., Walker, A.W., 2018. Assembly of 913 microbial genomes from metagenomic sequencing of the cow rumen. Nat. Commun. 9, 1–11.

Stolz, D., Papakonstantinou, E., Grize, L., Schilter, D., Strobel, W., Louis, R., Schindler, C., Hirsch, H.H., Tamm, M., 2019. Time-course of upper respiratory tract viral infection and COPD exacerbation. Eur. Respir. J. 54, 1900407.

Thng, Z.X., De Smet, M.D., Lee, C.S., Gupta, V., Smith, J.B., McCluskey, P.J., Thorpe, J.E., Kempen, J.H., Zierath, M., Nguyen, Q.D., 2021. COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs. Br. J. Ophthalmol. 105, 306–310. https://doi.org/10.1136/bjophthalmol-2020-316586.

Voznyy, T., Biggs, P.J., Schmeier, S., Friezle, F.A., Purcell, R.V., 2019. Metagenomics and transcriptomics data from human colorectal cancer. Scientific Data 6, 1–7. https://doi.org/10.1038/s41597-019-0117-3.

Wang, H., Dai, W., Peng, X., Zhou, Q., Wang, H., Yang, Y., Li, S. and Zheng, Y., 2018. Microbiota composition in upper respiratory tracts of healthy children in Shenzhen, China, differed with respiratory sites and ages. BioMed research international 2018. DOI: https://doi.org/10.1155/2018/6515670.

Wilson, D.N., 2016. The ABC of ribosome-related antibiotic resistance. MBio 7 (3), e00598-16. https://doi.org/10.1128/mBio.00598-16.

Wood, D.E., Lu, J., Langmead, B., 2019. Improved metagenomic analysis with Kraken 2. Genome Biol. 20, 257.

Wyprych, T.P., Wickramasinghe, L.C., Marshall, B.J., 2019. The influence of the microbiome on respiratory health. Nat. Immunol. 20, 1279–1290.

Yildiz, S., Mazel-Sanchez, B., Kandasamy, M., Manicassamy, B., Schmolke, M., 2018. Influenza A virus infection impacts systemic microbiota dynamics and causes quantitative enteric dysbiosis. Microbiome 6 (1), 1–17. https://doi.org/10.1186/s40168-017-0386-z.

Zhang, L., Forst, C.V., Gordon, A., Gussin, G., Geber, A.B., Fernandez, P.J., Ding, T., Lashua, L., Wang, M., Balmaseda, A., 2020. Characterization of antibiotic resistance and host-microbiome interactions in the human upper respiratory tract during influenza infection. Microbiome 8, 1–12.

Zheng, T., Li, J., Ni, Y., Kang, K., Misiakou, M.-A., Imamovic, L., Chow, B.K., Rode, A.A., Bytzer, P., Sommer, M., 2019. Mining, analyzing, and integrating viral signals from metagenomic data. Microbiome 7, 1–15.

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Wang, M., Balmaseda, A., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273.

Zuo, T., Zhang, F., Lui, G.C., Yeoh, Y.K., Li, A.Y., Zhan, H., Wan, Y., Chung, A., Cheung, C.P., Chen, N., 2020. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 159 (3), 944–955. https://doi.org/10.1053/j.gastro.2020.05.048,